Philipp Schwabl

8.1k total citations · 2 hit papers
140 papers, 5.1k citations indexed

About

Philipp Schwabl is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Philipp Schwabl has authored 140 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Hepatology, 114 papers in Epidemiology and 39 papers in Surgery. Recurrent topics in Philipp Schwabl's work include Liver Disease Diagnosis and Treatment (111 papers), Liver Disease and Transplantation (101 papers) and Hepatitis C virus research (33 papers). Philipp Schwabl is often cited by papers focused on Liver Disease Diagnosis and Treatment (111 papers), Liver Disease and Transplantation (101 papers) and Hepatitis C virus research (33 papers). Philipp Schwabl collaborates with scholars based in Austria, Germany and United States. Philipp Schwabl's co-authors include Thomas Reiberger, Michael Trauner, Theresa Bucsics, B. Liebmann, Philipp Königshofer, Mattias Mandorfer, Markus Peck‐Radosavljevic, Arnulf Ferlitsch, Bernhard Scheiner and Matthias Pinter and has published in prestigious journals such as Annals of Internal Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

Philipp Schwabl

131 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of Various Microplastics in Human Stool

2019 1.3k citations Philipp Schwabl, Philipp Königshofer et al. profile →
Detection of Microplastic in Human Placenta and Meconium in a Clinical Setting

2021 318 citations Philipp Schwabl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philipp Schwabl Austria	33	2.9k	2.8k	1.6k	1.0k	1.0k	140	5.1k
Theresa Bucsics Austria	23	1.3k 0.5×	1.3k 0.5×	1.3k 0.8×	817 0.8×	545 0.5×	78	2.9k
Thomas Reiberger Austria	50	6.7k 2.3×	6.5k 2.4×	1.3k 0.8×	817 0.8×	2.2k 2.2×	421	10.4k
Marcial Sebode Germany	20	1.2k 0.4×	1.1k 0.4×	408 0.2×	216 0.2×	376 0.4×	66	1.9k
Thomas Horvatits Germany	24	1.0k 0.4×	708 0.3×	410 0.2×	216 0.2×	349 0.3×	70	1.9k
Bin Xiong China	25	693 0.2×	442 0.2×	105 0.1×	82 0.1×	401 0.4×	143	2.4k
Takashi Nishiyama Japan	29	263 0.1×	93 0.0×	690 0.4×	107 0.1×	292 0.3×	105	3.1k
Tatsuya Koike Japan	31	131 0.0×	352 0.1×	381 0.2×	35 0.0×	581 0.6×	136	3.5k
Ying Sun China	23	354 0.1×	439 0.2×	106 0.1×	26 0.0×	236 0.2×	103	1.8k
Jun Kato Japan	37	938 0.3×	1.5k 0.5×	132 0.1×	22 0.0×	1.7k 1.7×	229	5.2k
Bumseok Kim South Korea	25	106 0.0×	373 0.1×	228 0.1×	54 0.1×	67 0.1×	92	2.4k

Countries citing papers authored by Philipp Schwabl

Since Specialization

Citations

This map shows the geographic impact of Philipp Schwabl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Schwabl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Schwabl more than expected).

Fields of papers citing papers by Philipp Schwabl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp Schwabl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Schwabl. The network helps show where Philipp Schwabl may publish in the future.

Co-authorship network of co-authors of Philipp Schwabl

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp Schwabl. A scholar is included among the top collaborators of Philipp Schwabl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp Schwabl. Philipp Schwabl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hofer, Benedikt, Benedikt Simbrunner, Philipp Königshofer, et al.. (2024). Inflammation remains a dynamic component of portal hypertension in regressive alcohol‐related cirrhosis. United European Gastroenterology Journal. 13(3). 317–329. 3 indexed citations

Hofer, Benedikt, Benedikt Simbrunner, Lukas Hartl, et al.. (2023). Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol‐related cirrhosis. Liver International. 43(10). 2220–2231. 36 indexed citations

Balcar, Lorenz, Bernhard Scheiner, Rafael Paternostro, et al.. (2023). Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease. JHEP Reports. 5(4). 100682–100682. 13 indexed citations

Paternostro, Rafael, Mathias Jachs, Lukas Hartl, et al.. (2023). Diabetes impairs the hemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes for hepatic decompensation. Zeitschrift für Gastroenterologie. 61(5). e194–e195.

Paternostro, Rafael, Mathias Jachs, Lukas Hartl, et al.. (2023). Diabetes impairs the haemodynamic response to non‐selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation. Alimentary Pharmacology & Therapeutics. 58(8). 805–813. 2 indexed citations

Hofer, Benedikt, Benedikt Simbrunner, David Bauer, et al.. (2022). Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatology Communications. 6(9). 2569–2580. 10 indexed citations

Schwabl, Philipp, Eva Hambruch, Grant R. Budas, et al.. (2021). The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines. 9(1). 60–60. 49 indexed citations

Semmler, Georg, Teresa Binter, K Kozbial, et al.. (2021). Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. Journal of Personalized Medicine. 11(4). 281–281. 4 indexed citations

Brachner, Andreas, Despina Fragouli, Iola F. Duarte, et al.. (2020). Assessment of Human Health Risks Posed by Nano-and Microplastics Is Currently Not Feasible. International Journal of Environmental Research and Public Health. 17(23). 8832–8832. 67 indexed citations

10.

Jachs, Mathias, Lukas Hartl, Benedikt Simbrunner, et al.. (2020). Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut. 70(9). 1758–1767. 58 indexed citations

11.

Brusilovskaya, Ksenia, Philipp Königshofer, David Bauer, et al.. (2020). Soluble guanylyl cyclase stimulation and phosphodiesterase‐5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct–ligated rats. United European Gastroenterology Journal. 8(10). 1174–1185. 26 indexed citations

12.

Semmler, Georg, Katharina Wöran, Bernhard Scheiner, et al.. (2020). Novel reliability criteria for controlled attenuation parameter assessments for non‐invasive evaluation of hepatic steatosis. United European Gastroenterology Journal. 8(3). 321–331. 38 indexed citations

13.

Costa, Dalila, Benedikt Simbrunner, Mathias Jachs, et al.. (2020). Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. Journal of Hepatology. 74(4). 819–828. 118 indexed citations

14.

Scheiner, Bernhard, Albert Friedrich Stättermayer, Philipp Schwabl, et al.. (2019). Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International. 40(2). 393–404. 17 indexed citations

15.

Semmler, Georg, Benedikt Simbrunner, Bernhard Scheiner, et al.. (2019). Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Gastroenterology and Hepatology. 34(12). 2164–2172. 10 indexed citations

16.

Semmler, Georg, Bernhard Scheiner, Philipp Schwabl, et al.. (2019). The impact of hepatic steatosis on portal hypertension. PLoS ONE. 14(11). e0224506–e0224506. 11 indexed citations

17.

Scheiner, Bernhard, Georg Semmler, Florian P. Maurer, et al.. (2019). Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver International. 40(1). 194–204. 58 indexed citations

18.

Mandorfer, Mattias, Bernhard Scheiner, Albert Friedrich Stättermayer, et al.. (2018). Impact of patatin‐like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology & Therapeutics. 48(4). 451–459. 24 indexed citations

19.

Payer, B.A., Thomas Reiberger, Philipp Schwabl, et al.. (2013). 593 LENALIDOMIDE AMELIORATES THE PORTAL HYPERTENSIVE SYNDROME IN NON-CIRRHOTIC AND CIRRHOTIC PORTAL HYPERTENSIVE ANIMALS. Journal of Hepatology. 58. S242–S243. 1 indexed citations

20.

Reiberger, Thomas, Gregor Ulbrich, Arnulf Ferlitsch, et al.. (2012). Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 62(11). 1634–1641. 228 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact